These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2141131)

  • 1. [Hydroxylation of debrisoquin in Parkinson's disease].
    Meillard MN; Bentué-Ferrer D; Brunet-Bourgin F; Morel G; Allain H
    Presse Med; 1990 May; 19(20):947-9. PubMed ID: 2141131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diurnal effects on debrisoquine hydroxylation phenotyping.
    Lee EJ
    Eur J Clin Pharmacol; 1988; 35(4):441-2. PubMed ID: 3197754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis.
    Chapman PH; Rawlins MD; Shuster S; Idle JR; Ritchie JC; Smith RL
    Eur J Clin Pharmacol; 1981; 21(3):257-8. PubMed ID: 6895622
    [No Abstract]   [Full Text] [Related]  

  • 4. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.
    Barbeau A; Cloutier T; Roy M; Plasse L; Paris S; Poirier J
    Lancet; 1985 Nov; 2(8466):1213-6. PubMed ID: 2866293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
    Du YL; Lou YQ
    Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoking, cancer, and Parkinson's disease.
    Barbeau A; Roy M; Cloutier T
    Ann Neurol; 1986 Jul; 20(1):105-6. PubMed ID: 3740811
    [No Abstract]   [Full Text] [Related]  

  • 7. Smoking, cancer, and Parkinson's disease.
    Golbe LI; Bernholc AA; Duvoisin RC
    Ann Neurol; 1987 May; 21(5):513. PubMed ID: 3592644
    [No Abstract]   [Full Text] [Related]  

  • 8. Polymorphic hydroxylation of Debrisoquine in man.
    Mahgoub A; Idle JR; Dring LG; Lancaster R; Smith RL
    Lancet; 1977 Sep; 2(8038):584-6. PubMed ID: 71400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Debrisoquine hydroxylation phenotype in SLE patients.
    Seideman P; Alván G
    Scand J Rheumatol; 1989; 18(1):63-4. PubMed ID: 2704985
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results.
    Vincent-Viry M; Deshayes S; Mothe O; Siest G; Galteau MM
    J Pharm Pharmacol; 1988 Oct; 40(10):695-700. PubMed ID: 2907535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
    Alván G; Grind M; Graffner C; Sjöqvist F
    Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereoselectivity of the 4-hydroxylation of debrisoquine in man, detected by gas chromatography/mass spectrometry.
    Meese CO; Fischer C; Eichelbaum M
    Biomed Environ Mass Spectrom; 1988 Jan; 15(2):63-6. PubMed ID: 3349209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
    Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
    Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Debrisoquine oxidative phenotyping and psychiatric drug treatment.
    Derenne F; Joanne C; Vandel S; Bertschy G; Volmat R; Bechtel P
    Eur J Clin Pharmacol; 1989; 36(1):53-8. PubMed ID: 2563689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer.
    Ohta S; Tachikawa O; Makino Y; Tasaki Y; Hirobe M
    Life Sci; 1990; 46(8):599-605. PubMed ID: 2308469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
    Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
    Arvela P; Kirjarinta M; Kirjarinta M; Kärki N; Pelkonen O
    Br J Clin Pharmacol; 1988 Nov; 26(5):601-3. PubMed ID: 3207564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.
    Spina E; Buemi AL; Sanz E; Bertilsson L
    Ther Drug Monit; 1989 Nov; 11(6):721-3. PubMed ID: 2595755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative polymorphism of debrisoquine in Parkinson's disease.
    Benitez J; Ladero JM; Jimenez-Jimenez FJ; Martinez C; Puerto AM; Valdivielso MJ; Llerena A; Cobaleda J; Muñoz JJ
    J Neurol Neurosurg Psychiatry; 1990 Apr; 53(4):289-92. PubMed ID: 2341841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.